May 2008
Volume 49, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2008
Effects of Bevacizumab, Pegaptanib and Ranibizumab on the Corneal Endothelium
Author Affiliations & Notes
  • R. Calvo
    General ophthalmology, Hospital Clinico de Valencia, Valencia, Spain
  • E. Tarrago
    General ophthalmology, Hospital Clinico de Valencia, Valencia, Spain
  • J. Vila
    General ophthalmology, Hospital Clinico de Valencia, Valencia, Spain
  • P. Bayo
    General ophthalmology, Hospital Clinico de Valencia, Valencia, Spain
  • O. Stirbu
    General ophthalmology, Hospital Clinico de Valencia, Valencia, Spain
  • L. Anselem
    General ophthalmology, Hospital General de Valencia, Valencia, Spain
  • F. Marin
    General ophthalmology, Hospital Clinico de Valencia, Valencia, Spain
  • Footnotes
    Commercial Relationships  R. Calvo, None; E. Tarrago, None; J. Vila, None; P. Bayo, None; O. Stirbu, None; L. Anselem, None; F. Marin, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 3953. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      R. Calvo, E. Tarrago, J. Vila, P. Bayo, O. Stirbu, L. Anselem, F. Marin; Effects of Bevacizumab, Pegaptanib and Ranibizumab on the Corneal Endothelium. Invest. Ophthalmol. Vis. Sci. 2008;49(13):3953. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose:
 

Bevacizumab, Pegaptanib and Ranibizumab are known to be safe for the human corneal endothelium in vitro, yet no in vivo effects were reported. We evaluate the morphologic and functional changes induced in the corneal endothelium by intravitreal injections of Bevacizumab, Pegaptanib and Ranibizumab.

 
Methods:
 

In this prospective clinical study, 60 eyes from 60 patients were assigned to receive intravitreal injection of either Bevacizumab (1.25mg) (N:20), Pegaptanib (0.3 mg) (N:20) or Ranbizumab (0.5mg) (N:20). The exclusion criteria were: Corneal dystrophy or corneal degeneration, ocular trauma history, pregnancy and a corneal endothelial density lower than 500 cells/mm2. Corneal endothelial analysis was performed one month pre- and postoperatively. Specular microscopy was used to capture the corneal endothelial images(SF-2000P,TopconTM), which were analyzed with Imagenet-2000 (TopconTM) software. The following variables were measured: Endothelial cell density (ECD), pleomorphism, expressed as the proportion of hexagonal cells (%Hex), and polymegathism, expressed as the coefficient of variation (CoV).

 
Results:
 

The anti VEGF intravitreal injections were administered in 60 patients (mean age 64±10.9 years). The preoperative average data were ECD: 1869, CoV: 28 and %Hex: 62. Postoperatively the average ECD was 1853, CoV: 28 and %Hex: 63. The results obtained in the three different treatment subgroups are shown in the attached table. No statistically significant differences were observed in the Bevacizumab, Pegaptanib and Ranibizumab subgroups.A subgroup analysis considering if the patients were phakic (38%) or pseudophakic (62%) was performed and no statistically differences were observed.

 
Conclusions:
 

This short term study suggests that Bevacizumab, Pegaptanib and Ranibizumab, at concentrations normally used in clinical practice, are not toxic to the human corneal endothelium, yet longer term studies are needed.  

 
Keywords: cornea: endothelium • vascular endothelial growth factor 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×